Cambridge Major Laboratories hires VP of Science and Technology

Dr Prasad Raje joins the company with 15 years of industry experience

Cambridge Major Laboratories, a chemistry outsourcing supplier to the pharmaceutical and biotechnology industries, has appointed Prasad Raje as VP of Science and Technology.

Raje will take overall responsibility for the company's active pharmaceutical ingredient (API) development organisation. He will also play a key role in the identification and implementation of new technologies and services.

Raje has more than 15 years of pharmaceutical industry experience. Prior to joining CML, he was president of Smithers Pharma Services, a CRO with expertise in analytical services, pharmaceutical R&D, and agrochemicals.

Prior to this, he held many roles at AMRI, initially as section head of chemical development, rising to president and managing director of AMRI India. He started his career as a senior research scientist at Abbott Laboratories.

You may also like

Manufacturing

Cambridge Major Labs supports Summit antibiotic project

The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Manufacturing

API launch from new Cambridge Major Laboratories facility

This is the first commercial launch of an active pharmaceutical ingredient from its newest facility
Ingredients

AAIPharma Charleston sterile manufacturing receives MHRA approval

<p>International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.</p>
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Subscribe now